Therapeutic effects of pazopanib treatment in patients with metastatic kidney cancer in real clinical practice

The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, and the choice of a first-line drug is a difficult task for an oncologist in actual clinical practice. The article offers the data analysis, including information on 15 treated patients, and presents clinical efficacy of the targeted drug pazopanib as the first-line therapy in patients with metastatic kidney cancer with various sites of metastatic foci. The drug showed evidence of a convincing response to treatment, especially for metastatic foci in the lungs and adrenal glands